Atia Vision Secures $20 Million Series D Funding to Advance Novel Intraocular Lens for Cataract and Presbyopia Treatment

VCBeat (WeChat Official Account: vcbeat) has learned that Atia Vision, a medical device company under the Silicon Valley healthcare innovation incubator Shifamed, recently announced the completion of a $20 million Series D preferred equity financing round. The round was led by Cormorant Asset Management, with participation from The Capital Partnership (TCP), AMED Ventures, and Shangbay Capital.

It is reported that Atia Vision will use the proceeds from this round of financing to advance the clinical development of a novel intraocular lens. Previously, Atia Vision completed a $3 million Series B financing in 2015 and a $10 million Series C financing in 2018.

Atia Vision is a medical device company focused on the field of ophthalmology. The Atia Vision team improves patient outcomes by developing safe and controllable presbyopia-correcting intraocular lenses (IOLs), with the aim of restoring comprehensive functional vision for cataract patients.

Globally, nearly 67 million people suffer from vision impairment due to lens opacification caused by cataracts, which can lead to blindness if not treated promptly. Cataract surgery involves removing the cloudy lens and replacing it with an artificial intraocular lens (IOL). Current treatment options have certain limitations in visual restoration, such as side effects including glare and halos. Atia Vision’s modular intraocular lens technology features an accommodating base that allows free control of the ciliary muscle, simulating the eye’s natural mechanism, along with fixed lens elements, helping patients restore vision from distance to near.

Mariam Maghribi, President and CEO of Atia Vision, stated, “With the support of this new round of financing, we look forward to further advancing clinical studies and demonstrating the performance of our technology, with the aim of comprehensively restoring functional vision for patients suffering from cataracts and presbyopia.”

“Strengthening the partnership with Atia Vision can provide next-generation solutions for the ophthalmic market,” commented Bihua Chen, Founder and CEO of Cormorant Asset Management. “Atia Vision’s leading technology uniquely addresses the clinical challenges currently faced in the field of visual impairment, where cataracts and presbyopia represent the two largest market segments.”

Shifamed is an advanced medical technology incubator that combines human-centered design, specialized engineering expertise, and in-house R&D facilities to develop new medical products from initial concept through to successful commercial launch. Shifamed leverages its proven entrepreneurial track record, having founded numerous advanced medical technology companies and brought high-value products to market.

Cormorant Asset Management is an employee-owned hedge fund headquartered in Boston, USA. The fund primarily provides portfolio management and advisory services to collective investment vehicles worldwide.

The Capital Partnership is a UK-headquartered venture capital firm. Established in 1998, the firm is dedicated to providing comprehensive asset management services and tailored investment solutions for institutional and private investors.

AMED Ventures is a venture capital firm headquartered in California, USA. The company is the venture capital arm of Amedisys (NASDAQ: AMED). Amedisys is an industry-leading healthcare company dedicated to bringing compassionate care into the home.

Shangbay Capital is a venture capital firm focused on investing in U.S.-based medical devices, biotechnology, and healthcare sectors. To date, the firm has completed five investments, with a total outward investment of $167.7 million.

(Compiled by Wang Yue)